SB

Sumita Bera

Active Director Director DIN 08117129
DIN 08117129 First appointment Apr 2018 Primary industry Electrnoics
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2018
Shareholding value •••• Premium profile

About Sumita Bera

Data last updated:

Sumita Bera is a Director at Often Pharmaceuticals Private Limited (since 2018). The company operates in Electrnoics. Often Pharmaceuticals Private Limited reported revenue of ₹28,763 (FY 2023).

DIN 08117129
Primary Designation Director
Industry Electrnoics
First Appointment 23 Apr 2018
Oldest Company Age 8 yrs
Largest company Often Pharmaceuticals Private Limited · ₹28,763 (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Apr 20182018₹28,763 (FY 2023)Active

Board colleagues of Sumita Bera

NameDINCompanyDesignation
Dipanjan Nath08117128Often Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Often Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sumita Bera

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sumita Bera

Sumita Bera currently holds 1 directorship: Often Pharmaceuticals Private Limited (Director, since 23 Apr 2018, revenue ₹28,763 (FY 2023)).

Sumita Bera was first appointed on 23 Apr 2018 as Director at Often Pharmaceuticals Private Limited.

The current boards of Sumita Bera's companies include Dipanjan Nath (Often Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available